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Effects of curcumin on stem-like cells in human
esophageal squamous carcinoma cell lines
Taghreed N Almanaa1, Michael E Geusz1 and Roudabeh J Jamasbi1,2*
Abstract
Background: Many cancers contain cell subpopulations that display characteristics of stem cells. Because these
cancer stem cells (CSCs) appear to provide resistance to chemo-radiation therapy, development of therapeutic
agents that target CSCs is essential. Curcumin is a phytochemical agent that is currently used in clinical trials to test
its effectiveness against cancer. However, the effect of curcumin on CSCs is not well established. The current study
evaluated curcumin-induced cell death in six cancer cell lines derived from human esophageal squamous cell
carcinomas. Moreover, these cell lines and the ones established from cells that survived curcumin treatments
were characterized.
Methods: Cell loss was assayed after TE-1, TE-8, KY-5, KY-10, YES-1, and YES-2 cells were exposed to 20–80 μM
curcumin for 30 hrs. Cell lines surviving 40 or 60 μM curcumin were established from these six original lines. The
stem cell markers aldehyde dehydrogenase-1A1 (ALDH1A1) and CD44 as well as NF-κB were used to compare
CSC-like subpopulations within and among the original lines as well as the curcumin-surviving lines. YES-2 was
tested for tumorsphere-forming capabilities. Finally, the surviving lines were treated with 40 and 60 μM curcumin to
determine whether their sensitivity was different from the original lines.
Results: The cell loss after curcumin treatment increased in a dose-dependent manner in all cell lines. The
percentage of cells remaining after 60 μM curcumin treatment varied from 10.9% to 36.3% across the six lines. The
cell lines were heterogeneous with respect to ALDH1A1, NF-κB and CD44 expression. KY-5 and YES-1 were the least
sensitive and had the highest number of stem-like cells whereas TE-1 had the lowest. The curcumin-surviving lines
showed a significant loss in the high staining ALDH1A1 and CD44 cell populations. Tumorspheres formed from
YES-2 but were small and rare in the YES-2 surviving line. The curcumin-surviving lines showed a small but
significant decrease in sensitivity to curcumin when compared with the original lines.
Conclusion: Our results suggest that curcumin not only eliminates cancer cells but also targets CSCs. Therefore,
curcumin may be an effective compound for treating esophageal and possibly other cancers in which CSCs can
cause tumor recurrence.
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Background
Esophageal cancer is the eighth most common cancer
worldwide and the sixth most common cause of death
among cancers [1]. Of the two types of esophageal can-
cer, adenocarcinoma (EAC) and squamous cell carcin-
oma (ESCC), 90% are ESCC, with rates increasing
significantly in developing countries [2]. About 13% of
ESCC patients survive for five years after diagnosis [3].
The prognosis of ESCC is often poor due to lack of ef-
fective treatment [4]. As a result of this limitation, newer
agents and novel approaches are imperative. Of particu-
lar interest is the chemotherapeutic application of curcu-
min, the major active ingredient of turmeric (Curcumin
longa) [5-8]. Curcumin induces cell death in some can-
cers, such as gastric and colon cancers [9], human mel-
anoma [10], and lung cancer [11] without major
cytotoxic effects on healthy cells [12,13]. Curcumin
induces cell death through a variety of mechanisms by
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targeting pathways acting through a range of transcrip-
tion factors, membrane receptors, kinases, and cytokines
(reviewed by Anand et al. [14]). Therefore, curcumin
has a potential treatment value for cancer either alone
[15] or in combination with other treatments, namely
chemotherapy [16] and radiation treatments [17]. Al-
though it is rapidly degraded and thus may have little ef-
fect outside of the digestive tract [18,19], curcumin
could be effective for treating ESCC because of its direct
contact with epithelial cells lining the esophagus during
ingestion.
One possible reason for the poor prognosis of ESCC is
the presence of cancer stem cells (CSCs) in the tumor
[20,21]. It is believed that CSCs regenerate themselves
and differentiate into non-CSCs that constitute most of
the tumor volume [22-25]. Furthermore, CSCs tend to
resist currently used cancer treatments, specifically
chemotherapy and radiation therapy [26-28]. Therefore,
the development of effective treatments for cancer
should target this cell subpopulation [29]. Interestingly,
curcumin with or without 5-fluorouracil and oxaliplatin
significantly reduced the number of cells showing CSC-
markers CD44 and CD166 in a colon cancer cell line
that had survived previous treatment with 5-fluorouracil
[30]. More recently, Nautiyal et al. [31] reported that a
combination of curcumin and the chemotherapeutic
agent dasatinib eliminates mRNA stem cell markers—
specifically, ALDH, CD44, CD133, and CD166—that are
enriched in the chemo-resistant colon cancer cells. Simi-
larly, Fong et al. [32] reported that curcumin decreased
the side-population associated with stem cell popula-
tions in the C6 glioma cell line, as determined by nega-
tive Hoechst 33342 nuclear staining.
CSCs have high expression of aldehyde dehydrogenase
(ALDH) that can be used as a potential marker for iden-
tifying and isolating CSCs [33-35]. ALDH is a detoxify-
ing enzyme responsible for the oxidation of both
intracellular aldehydes and xenobiotic aldehydes such as
cyclophosphamide [36,37]. High ALDH expression could
also indicate the aggressiveness, invasiveness, or meta-
static capability associated with different cancers [27,38].
ALDH1A1 is a member of the ALDH family that
participates in alcohol metabolism and offers cellular
protection against cytotoxic drugs [39]. Although immu-
nohistochemistry with a specific antibody against
ALDH1A1 has been used to identify both somatic
stem cells and cancer stem cells [38,40,41], ALDH1A1
expression has not been evaluated in human esophageal
cancer.
Another marker for CSCs is CD44 (cluster of differen-
tiation 44). CD44 is an integral cell membrane glycopro-
tein involved in cell-cell interaction [42]. CD44 has been
identified in many types of CSCs, including breast can-
cer [43], head and neck cancer [44], gastric cancer [45]
as well as ESCC [46]. High CD44 expression is also asso-
ciated with metastatic and invasive capabilities [47].
An additional property of cancer stem cells (CSCs) is
the ability to grow as non-adherent spheres when cul-
tured in serum-free medium supplemented with basic
fibroblast growth factor (bFGF) and epidermal growth
factor (EGF) [48-50]. Recently, non-adherent sphere cul-
tures have been used as an effective approach to enrich
and identify stem cells or CSCs [51,52].
In this study, curcumin-surviving cell lines were estab-
lished from six human ESCC lines. The CSC markers
ALDH1A1 and CD44, curcumin toxicity, and tumor-
sphere formation were examined. When the surviving
cell lines were compared with the original untreated
lines, the results indicated that curcumin produced a
permanent reduction in the CSC-like subpopulation of
these cells.
Methods
Cell lines and culture conditions
The six human esophageal squamous cancer cell lines
(TE-1, TE-8, KY-5, KY-10, YES-1, and YES-2) were
obtained from various sources [53-56]. The cell lines
were cultured in Dulbecco's modified eagle medium
(DMEM) supplemented with penicillin (100 units/ml),
streptomycin (100 μg/ml), L-glutamine (2 mM) (GIBCO,
Invitrogen, NY), and 10% fetal bovine serum (FBS, Sum-
mit Biotechnology, Ft. Collins, CO). This medium was
designated as complete DMEM. The cells in culture
were maintained in 100-mm tissue culture dishes (Falcon,
Lincoln Park, NJ) at 37°C in a humidified incubator con-
taining 5% CO2. When the cells reached near confluency,
they were washed with phosphate-buffered saline (PBS)
once and incubated with trypsin (Trypsin-EDTA 0.25%,
GIBCO, Invitrogen, NY) for two min. After incubation,
the cells were washed once with complete DMEM to
inactivate trypsin. The cells were then collected by centri-
fugation at 800 x g, resuspended in complete DMEM and
plated into new culture dishes.
Morphological examination
To examine the morphology of the ESCC cell lines, each
cultured line was trypsinized, washed and counted using
a hemocytometer (Hausser Scientific, PA). The cells
were then plated into 100-mm dishes (1×105 cells/plate)
in complete DMEM and incubated at 37°C. When the
cells reached near confluency, approximately 70-75%,
the cultures were photographed using a phase-contrast
microscope (Olympus CK40) equipped with a color
digital camera (Kodak M575).
Curcumin treatment
To determine the effect of different doses of curcumin
on the ESCC lines, each cell line was plated in 24-well
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plates (Corning) at a density of 5×104 cells/well in
complete DMEM, and incubated at 37°C. Curcumin
(Sigma-Aldrich, St Louis, MO) was dissolved in dimethyl
sulfoxide (DMSO) to make a stock solution of 20 mM
curcumin. For each experiment, stock solution was diluted
to the final concentrations (20, 30, 40, 60 and 80 μM) in
complete DMEM. Twenty-four hours after plating, the
wells were washed with PBS once, and 1 ml of each curcu-
min dosage was added (4 wells/dosage) and incubated for
30 hrs. Four other wells received complete DMEM or
complete DMEM with 0.2% DMSO as controls. The in-
hibition of cell growth in response to curcumin treatment
was assayed with the crystal violet staining assay according
to a standard protocol [57]. Briefly, the cells in each well
were washed once with PBS, stained with 200 μl crystal
violet in 50% ethanol (10 mg/ml), and incubated at room
temperature for 10 min. The crystal violet was then
removed and the wells were washed two times with dis-
tilled water, and 600 μl of 1% sodium dodecylsulfate
(SDS) in water was added to each well. The plates were
maintained overnight at room temperature on a shaker
to dissolve the dye. Absorbance was read at 490 nm
using a Wallac Victor 1420 Multilabel plate reader
(Perkin Elmer, Waltham, MA). The background readings
from the SDS solution were subtracted from each read-
ing and the percentage of cells remaining after curcumin
treatment was calculated.
Curcumin-surviving subpopulation
To select for a curcumin-surviving cell subpopulation,
each of the ESCC cell lines was cultured in 100-mm
dishes (1×105 cells/dish) with complete DMEM and incu-
bated at 37°C until reaching near confluency, approxi-
mately 80%. After incubation, the medium was removed
and the cells were incubated in complete DMEM contain-
ing either 40 or 60 μM curcumin dissolved in 0.2% DMSO
for 30 hrs. After incubation, the medium-containing cur-
cumin was removed and replaced with complete DMEM
to allow cells that survived the treatment to grow. After
the surviving cells formed colonies (normally four weeks
after treatment), the colonies were counted, trypsinized,
and passaged. The cell lines that developed were desig-
nated the curcumin-surviving cell lines.
Exposure of the curcumin-surviving cell lines to curcumin
To compare the effect of curcumin on the original cell
lines and the curcumin-surviving cell lines, the
curcumin-surviving lines were cultured in 24-well plates
(5×104 cells/ well) in complete DMEM and incubated at
37°C. Twenty-four hours after plating, wells were treated
with 40 or 60 μM curcumin and incubated for 30 hrs
(4 wells/dosage). The inhibition of cell growth in re-
sponse to curcumin treatment was assayed with the
crystal violet staining assay as described above.
Immunocytochemistry
To assess the expression of the stem cell markers
ALDH1A1 and CD44 in both the original ESCC cell
lines and the curcumin-surviving cell lines, each line
was grown on glass cover slips in complete DMEM.
After two days, the cover slips were rinsed with PBS and
fixed with methanol for 5 min. The cover slips were then
washed three times with PBS, exposed to 0.3% hydrogen
peroxide for 3 min, and rinsed three times with PBS.
Next, the cells were blocked with normal goat serum
(Rockland, Gilbertsville, PA) at 1:100 dilution in PBS for
30 min. The cover slips were then incubated with a pri-
mary antibody for 2 hrs at room temperature, after
which the cover slips were washed three times with PBS
and incubated with a secondary antibody for 30 min. For
ALDH1A1 staining, a rabbit anti-human ALDH1A1
antibody (Proteintech Group, Chicago, IL) at 1:100 dilu-
tion and a goat anti-rabbit antibody conjugated with
horseradish peroxidase (Rockland, Gilbertsville, PA) at
1:1000 dilution were used. For CD44 staining, a mouse
monoclonal anti-human CD44 antibody (BD Bios-
ciences, Franklin Lakes, NJ) at 1:10 dilution and a goat
anti-mouse horseradish peroxidase-conjugated antibody
(Sigma-Aldrich, St Louis, MO) at 1:40 dilution were
used. The cells were then reacted with ImmunPACT
DAB (Vector Laboratories, Burlingame, CA) for 10 min.
The cover slips were washed three times with water,
dehydrated in an ethanol series, cleared with Citrosolve
(Fisher, Pittsburgh, PA), and mounted on glass slides
with Permount (Fisher, Pittsburgh, PA). Control cover-
slips did not receive the primary antibody but were
otherwise treated identically.
Image analysis
The images of cell cultures immunostained for
ALDH1A1 or CD44 were analyzed with ImageJ (NIH)
and OriginLab (OriginLab) software. To determine the
intensity of staining, all cells were imaged with a 12-bit
digital camera (MicroMax, Princeton Instruments) and a
Zeiss Axiophot microscope. The images were thre-
sholded identically using a pixel intensity (brightness)
value of 500 analog-to-digital units (ADUs). For count-
ing cells, ImageJ was used to identify cells within a nor-
mal size range (500–4000 pixels in area) that did not
touch the edge of the image.
Enzyme-linked immunosorbent assay (ELISA)
The level of RelA (p65), a subunit of transcription factor
NF-κB, and ALDH1A1 was examined in both curcumin-
surviving cells and original cell lines. ELISA was per-
formed as described previously [58]. Briefly, each cell
line was cultured in 96-well plates (5×104 cells/well) and
incubated for 24 hrs at 37°C. After incubation, the wells
were washed once with PBS, fixed with methanol for 5
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min, and then washed twice with PBS. Anti-p65 at 1:50
dilution (Santa Cruz Biotechnology, SC-109, 200 μg/ml)
and anti-ALDH1A1 at 1:500 dilution (Proteintech
Group, 15910-1-AP, 133 μg/ml) were prepared in
complete DMEM. The wells were incubated with 100 μl
of each antibody (3 wells/antibody dilution) for 2 hrs at
37°C. After incubation, the wells were washed with PBS
three times and incubated with 100 μl/well of β-
galactosidase-conjugated goat anti-rabbit secondary anti-
body (Southern Biotech, Birmingham, AL, 1:500 dilution
in complete DMEM) for 2 hrs at 37°C. After incubation,
the wells were washed with PBS three times and 100 μl/
well of substrate solution (1 mg/ml p-nitrophenyl-β-D-
galactopyranoside in phosphate buffer, pH 8.0) was
added and incubated at 37°C for one hour in darkness.
The development of yellow color indicated a positive re-
action. The antigen-antibody reactions were measured
by determining the optical density (O.D.) at 410 nm
using a microwell plate reader (MR-600, Dynatech Lab
Inc.).
Tumorsphere formation
To examine the ability of the cell line to form spheres,
YES-2 and YES-2S cell lines were cultured in stem cell
medium. Cells were maintained as a monolayer in
complete DMEM until they were nearly confluent. Cells
were trypsinized, collected, and washed two times to re-
move serum, then suspended in serum-free DMEM/F12
supplemented with penicillin (100 units/ml), strepto-
mycin (100 μg/ml), 20 ng/ml human epidermal growth
factor (EGF), 20 ng/ml human basic fibroblast growth
factor (bFGF), and B27 supplement (Invitrogen,
Carlsbad, CA, USA). The cells were subsequently cul-
tured in ultra-low attachment 60-mm plates (Corning
Inc., Corning, NY, USA) at a density of 10.000 cells/
plate. Plates were incubated at 37°C in a humidified 5%
CO2 incubator for a week and then formation of free-
floating spheres was evaluated. The experiment was per-
formed in triplicate.
Statistical analysis
For statistical analysis OriginPro 7.5 (OriginLab) was
used. Statistical comparisons between two groups were
made using Student’s t-test. For comparing more than
two groups, one-way analysis of variance (ANOVA) was
used followed by the Scheffe multiple comparisons test
with a significance of p< 0.05. All errors are shown as
standard deviation (SD).
Results
Morphological characteristics of the ESCC lines
The characteristics of patients, tumors, and esophageal
cell lines derived from each tumor are listed in Table 1.
All cell lines grew as adherent monolayers with unique
morphological characteristics in size and shape as shown
in Figure 1. The morphological characteristics of the
ESCC cell lines were similar to the morphologies that
were originally described [53-56].
Cytotoxic effect of curcumin on the ESCC lines
To assess the sensitivity of the six human ESCC lines to
curcumin, the cell lines (TE-1, TE-8, KY-5, KY-10, YES-1,
and YES-2) were plated in 24-well plates and maintained
in culture for 24 hrs and then exposed to 20, 30, 40, 60,
and 80 μM curcumin and to 0.2% DMSO as a control for
30 hrs. The resulting cell density was determined by a
standard crystal violet assay. The cell density remaining
after the treatment is shown in the dose–response curves
(Figure 2). Curcumin caused a reduction in cells in a
dosage-dependent manner in all six ESCC cell lines. How-
ever, KY-5 had the highest percentage of cells remaining at
the highest curcumin concentration, and the YES-2 cell
line had the lowest percentage of cells remaining. When
the cell lines were ranked from low to high according to
their sensitivity to 60 μM curcumin the order was: KY-5,
YES-1, TE-8, TE-1, KY-10, and YES-2. The range of the
percentage of cells remaining after the curcumin treat-
ment across the six cell lines was 10.9% to 36.3% at 60 μM
curcumin. At 60 μM curcumin, the YES-2 and KY-10 were
more sensitive than the KY-5, YES-1, TE-8, and TE-1
(p<0.05 according to one-way ANOVA, F=16.44,
p<0.0001).
Comparison of the ESCC lines and the curcumin-surviving
lines
According to the dose–response results, 60 μM curcu-
min was chosen to select for the curcumin-surviving cell
line subpopulations, indicated by “S”. To establish this
subpopulation, 1×105 cells from each ESCC line were
plated into 100-mm tissue culture dishes and incubated
until they reached near confluency. The cells were then
exposed to 60 μM curcumin for 30 hrs, and the surviv-
ing colonies formed were counted. The number of col-
onies formed after 60 μM curcumin treatment varied
among the six cell lines. YES-2 cell line did not form
any colony at the concentration of 60 μM curcumin,
therefore it was treated with a lower concentration (40
μM) curcumin. The number of surviving colonies
formed after 60 μM curcumin was 0, 8, 17, 19, 25, and
too many colonies to count for YES-2, TE-1, TE-8, KY-
10, YES-1, and KY-5, respectively. The KY-5 cell line had
the highest number of surviving colonies, whereas the
YES-2 cell line did not form any colonies after 60 μM
curcumin but formed 15 colonies after treatment with
40 μM curcumin.
To further distinguish between the original ESCC cell
lines and the curcumin-surviving lines, we measured
NF-κB, ALDH1A1, and CD44 levels. We also examined
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the effect of curcumin on these lines and their ability to
form tumorspheres.
Evaluation of ALDH1A1 and NF-κB levels using ELISA
The ALDH1A1 and NF-κB expression levels were mea-
sured in the original ESCC lines and the curcumin-
surviving lines using ELISA. As shown in Figure 3A and
3B, the levels of ALDH1A1 and NF-κB showed signifi-
cant variation among the six original ESCC lines.
ALDH1A1 expression level was significantly higher in
KY-5 than in all other lines. YES-2 had higher
ALDH1A1 expression than YES-1, TE-8, KY-10 and TE-
1. Also, KY-5 showed significantly higher NF-κB levels
than YES-1, TE-8, KY-10 and TE-1. YES-2 had higher
NF-κB expression than TE-8, KY-10 and TE-1, and YES-1
was higher than TE-1. All significant differences were
based on one-way ANOVA (F=152.71, p<0.0001 for
ALDH1A1 and F=55.73, p<0.0001 for NF-κB). In the ori-
ginal cell lines, ALDH1A1 expression was positively cor-
related with NF-κB expression as shown in Figure 3C
(R=0.903, linear regression, p=0.0134). The KY-5 cell line
showed the highest levels of ALDH1A1 and NF-κB,
whereas the TE-1 cell line showed the lowest levels of
both markers. However, there was no relationship be-
tween ALDH1A1 and NF-κB expression in the surviving
lines as shown in Figure 3D (R= −0.004, p=0.994).
The results also showed that the curcumin-surviving
lines had lower ALDH1A1 levels when compared with the
original cell lines, except for TE-1 (Figure 3A). This de-
cline was not a function of ALDH1A1 levels in the ori-
ginal lines as shown in Figure 3E (R=−0.285, p=0.583). In
addition, the results also showed that KY-5S, YES-1S and
YES-2S had lower NF-κB levels when compared with the
original cell lines (Figure 3B). However, TE-1S and TE-8S
Figure 1 Morphology of the six ESCC cell lines. Each cell line had a unique cell shape and size as shown by phase contrast microscopy. Cell
morphology agreed with published descriptions [53-56]. Scale bar equals 100 μm.
Table 1 Reported characteristics of cell lines derived from esophageal squamous cell carcinomas
Cell line Patient information Cell line properties References
Age Tumor
differentiation
Cell doubling
time (hrs)
Tumorigenicity Morphology
KY-5 (KYSE-50) 58 Poor 28.2 Yes Growing as a cluster with smaller cells in the center [53]
KY-10 (KYSE-110) 63 Poor 19.1 Yes Spindle shape [53]
YES-1 50 Poor 35.2 Yes Polygonal to spindle shape [54]
YES-2 81 Moderate 23.7 Yes Polygonal epithelial shape [55]
TE-1 58 Well 27.2* Yes Spindle shape [56]
TE-8 63 Moderate 25.7* N.A. Spindle shape [56]
All tumors were from male patients. Cell line tumorigenicity was determined by subcutaneous injection into nude mice. N.A. = not available.
*Doubling time was determined in the present study.
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showed increased NF-κB levels relative to the original
lines, but KY-10S showed no difference from KY-10. As
shown in Figure 3F, the change in NF-κB levels between
original and surviving lines was inversely correlated with
NF-κB levels in the original lines (R= −0.901, p=0.0139).
Assessment of ALDH1A1 expression in ESCC and
curcumin-surviving lines by immunocytochemistry
ALDH1A1 immunostaining was examined in the six ori-
ginal ESCC lines by measuring the staining intensity of
individual cells. As shown in Figure 4, high ALDH1A1
staining was detected in the cytoplasm of the six cell
lines and this was significantly different among the lines
according to mean intensity (F=307, p<0.0001). Staining
for ALDH1 was significantly higher in KY5 than in all
other lines. YES-2 had significantly higher staining than
YES-1, TE-8, TE-1, and KY-10. Also, TE-8 staining was
significantly higher than YES-1, TE-1 and KY-10.
Within all of the six original lines, there were two sub-
populations, each with its own distinctive peak in the
histogram, (high and low ALDH1A1-staining subpopula-
tions), as shown in Figure 5. The high and low subpopu-
lations were separated by the minimum between the two
peaks. Mean staining intensity was significantly different
between the two subpopulations (F=941, p<0.0001). The
mean intensity of the high-staining subpopulation was
about twice the mean of the low-intensity cells. For ex-
ample, the mean of the low intensity population in KY-5
was 192.56 ± 80.48, and the mean of the high intensity
was 477.80 ± 93.82. When arranged by mean intensity of
the high-staining subpopulation, the cell lines were
ranked: KY-5 (477.80 ± 93.82), YES-2 (243.77 ± 33.54),
TE-8 (222.23 ± 42.02), KY-10 (199.70 ± 39.31), YES-1
(180.88 ± 28.31), and TE-1 (149.67 ± 16.29). When the
percentage of cells in the high-staining subpopulation
was analyzed, KY-5 showed the greatest percentage and
TE-1 the lowest. The percentage of cells with high
ALDH1A1 staining ranged from 5.6% to 40.4%.
Like the original cell lines, there was a significant high-
staining subpopulation within each surviving line except
TE-1S and TE-8S, as shown in Figures 4 and 5
(F=1400.88, p<0.0001). As in the original lines, the high-
staining subpopulation mean intensity was about twice
that of the low staining subpopulation. For example, the
mean of the low staining subpopulation in KY-5S was
172.59 ± 83.55 and the high was 496.93 ± 108.38. When
arranged by mean intensity of the high-staining subpopu-
lation, the cell lines were ranked: KY-5S (496.93 ±108.37),
YES-2S (234.95 ±28.23), KY-10S (206.67 ±26.77), and
YES-1S (145.55 ± 24.52).
Interestingly, each of the curcumin-surviving cell lines
showed a significant decrease in the percentage of cells
in the high-staining subpopulation when compared to
their corresponding original line (t=3.7235, p= 0.0040).
This decline is visible as a loss of nearly all of the cells
in the high-staining subpopulations (Figure 5). TE-8 and
TE-1 showed complete loss of its high-staining popula-
tion. The percentage of cells in the high-staining subpo-
pulations of the curcumin-surviving lines ranged from 0
for TE-8S and TE-1S to 12.2% for KY-5S.
Detection of CD44-expressing cells in ESCC and
curcumin-surviving lines
CD44 expression was examined in two ESCC lines with
high ALDH1A1 expression, YES-1 and YES-2, and their
corresponding curcumin-surviving lines, YES-1S and
YES-2S. As shown in Figure 6, the cells in all four lines
were distributed into two significantly different subpopu-
lations according to CD44-staining intensity (F=228,
p<0.0001). The mean of the high intensity-staining cells
was about twice that of low intensity-staining cells. For
Figure 2 Effects of curcumin on six ESCC cell lines. At 60 μM curcumin, YES-2 and KY-10 were more sensitive than KY-5, YES-1, TE-8, and TE-1
(p<0.05, ANOVA, F=16.44, p<0.0001). Cell loss was measured by a standard crystal violet assay after incubation with 20 to 80 μM curcumin for
30 hrs. Each point represents the effect of one curcumin dosage (20, 30, 40, 60 or 80 μM). For 40 and 60 μM the error bar indicates mean (±SD)
of three experiments.
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example, the mean intensities of the low- and high-
staining YES-1 subpopulations were 175.47 ± 89.99 and
446.47 ± 31.21. The mean intensity of the high-staining
cells of the other three lines was 438.96 ± 55.38, 463.79 ±
50.66, and 470.20 ± 53.77 for YES-2, YES-1S, and YES-2S,
respectively. The percentage of high-staining cells in the
original lines was 12.11% and 4.82% for YES-2 and YES-1,
respectively. The percentage of high CD44-staining cells
decreased in the curcumin-surviving cell lines to 8.67%
and 2.70% for YES-2S and YES-1S, respectively.
Tumorsphere formation
The ability of the original YES-2 and its surviving line
(YES-2S) to form three-dimensional spheres in serum-free
medium containing EGF and bFGF on low-attachment
plates was examined. This procedure has been reported
Figure 3 NF-κB and ALDH1A1 levels in original ESCC cell lines and curcumin-surviving lines measured using ELISA. (A) ALDH1A1
expression levels varied between the six original ESCC lines. ALDH1A1 expression was significantly higher in KY-5 than in all other lines (asterisk).
YES-2 had higher expression than the other four lines (filled square). (B) NF-κB levels also varied between the cell lines. KY-5 showed significantly
higher NF-κB levels than the other four lines (asterisk). YES-2 also had higher NF-κB levels than the other three cell lines (filled square). YES-1 was
higher than one line (filled circle). All significant differences were based on one-way ANOVA (F=152.71, p<0.0001 for ALDH1A1 and F=55.73,
p<0.0001 for NF-κB). (C) ALDH1A1 and NF-κB levels in the original cell lines showed a strong correlation (R=0.903, linear regression, p=0.0134). (D)
This relationship was absent in the surviving lines (R=−0.004, p=0.994). (E) All cell lines but one (TE-1) had lower ALDH1A1 levels in the surviving
lines than in the original lines. This decline was not a function of ALDH1A1 levels in the original lines (R=−0.285, p=0.583). (F) In contrast, the
change in NF-κB levels between original and surviving lines was inversely correlated with NF-κB levels in the original lines (R=−0.901, p=0.0139).
The average optical density at 410 nm of three wells (±SD) is shown. Curcumin-surviving cell lines were derived from cells that survived 60 μM
curcumin treatment, except YES-2S, which survived 40 but not 60 μM curcumin.
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by others to identify stem cells [59-61]. Under these con-
ditions, YES-2 cells grew as anchorage-independent
spheres after 7 days of culture (Figure 7A), whereas YES-
2S cells did not form any spheres at that time. The average
number of spheres formed by YES-2 was 206 ± 20.8
(mean of all spheres in 3 plates ±SD) and sphere size ran-
ged from 70–200 μm in diameter. However, YES-2S cells
were only able to form spheres after two weeks, and the
average number of spheres was 4.3 ±5.13 (mean of all
spheres in 3 plates ±SD) with diameters ranging from 40–
100 μm (Figure 7B). These results indicated that the ori-
ginal line produces greater numbers of spheres that are
larger in size and grow faster than the spheres in the
curcumin-surviving line.
Effect of curcumin treatment on the
curcumin-surviving lines
To compare the effect of curcumin on the ESCC lines and
curcumin-surviving lines, the curcumin-surviving cell
lines were passaged four times and treated with 40 or 60
μM curcumin. The resulting cell density was determined
by standard crystal violet assay and the percentage of cells
remaining after treatment was calculated for each line
(Figure 8). This experiment was repeated three times. A
two-way ANOVA revealed a small but significant increase
in resistance in the curcumin-surviving cell lines relative
to the original lines when tested with either of the two-
curcumin concentrations (factor 1; 40 μM: F=5.132,
p=0.031; 60 μM: F=8.358, p=0.008; Scheffe post hoc test).
YES-1S showed the greatest change from its original cell
line. The cell lines also differed significantly from each
other in their ability to survive the curcumin treatments
(factor 2; 40 μM: F=9.508, p<0.001; 60 μM: F=12.71,
p<0.001; Scheffe test).
Discussion
Esophageal cancer is a highly aggressive malignant dis-
ease resulting in low patient survival. Because of the
Figure 4 ALDH1A1 immunocytochemistry. After immunostaining for ALDH1A1, all six ESCC lines and curcumin-surviving lines showed distinct
high and low-staining cells. Cells were stained 48 hrs after plating and then staining intensity of individual cells was quantified. “S” indicates
curcumin-surviving cell lines. Scale bar = 100 μm.
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poor success rate of standard therapies, innovative
approaches for treatment have been tested, and two
studies have examined whether curcumin could be a po-
tential candidate for esophageal cancer treatment. In one
study, Hartojo et al. [62] examined the effects of curcu-
min on the NF-κB activity and cell viability of
esophageal adenocarcinoma and also in combination
with 5-fluorouracil (5-FU) and cisplatin. In the other
study, O’Sullivan-Coyne et al. [63] investigated the effect
of curcumin-induced apoptosis on esophageal cancer
cells. In the present investigation, we selected six
esophageal squamous cell carcinoma lines to evaluate
Figure 5 ALDH1A1 immunostaining of original ESCC cell lines and curcumin-surviving lines. The histograms summarize cell counts
according to staining intensity as shown in Figure. 4. The maxima of the high-staining subpopulations in the original cell lines are shown by the
asterisk. Curcumin-surviving cell lines, indicated with “S”, showed a significant loss of the high-staining subpopulation. The mean intensity of
ALDH1A1 expression was significantly different among the original lines (F=307.047, p<0.0001). KY-5 staining was significantly higher than all
other lines. YES-2 was significantly higher than YES-1, TE-8, TE-1, and KY-10. Also, TE-8 was significantly higher than YES-1, TE-1 and KY-10. The
mean intensity of ALDH1A1 expression levels was also significantly different among the surviving lines (F=611.440, p<0.0001). KY-5S staining was
significantly higher than all other surviving lines. YES-2S was significantly higher than TE-8S, KY-10S, TE-1S and YES-1S. TE-8S was higher than
KY-10S, YES-1S and TE-1S. Also, KY-10S was significantly higher than YES-1S and TE-1S. The mean intensity of high-staining cells in the original cell
lines was 477.80 ± 93.82, 243.77 ± 33.54, 222.23 ± 42.02, 199.70 ± 39.31, 180.88 ± 28.31, and 149.67 ± 16.29 for KY-5, YES-2, TE-8, KY-10, YES-1, and
TE-1, respectively. The mean intensity of high-staining cells in the surviving cell lines was 496.93 ±108.38, 234.95 ±28.23, 206.67 ±26.77, and
145.55 ± 24.52 for KY-5S, YES-2S, KY-10S, and YES-1S.
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their sensitivity to curcumin. The six cell lines
were found to be similar morphologically to what was
shown in the original publications introducing these
lines [53-56] (Figure 1, Table 1).
When the cell lines were treated with curcumin (20–
80 μM) for 30 hrs there was a reduction in cell number
in all lines in a dose-dependent manner, consistent with
studies using breast, lung, and colorectal cancer cell
lines (reviewed by Anand et al. [14]), and esophageal
cancer cell lines (OE19, OE33, OE21, KYSE450) [63].
We found a significant difference in the response of the
six ESCC lines to curcumin according to the crystal
violet assay. The KY-5 cell line, for example, showed
about three times more cells remaining after 60 μM cur-
cumin than YES-2 (Figure 2).
This is the first study to characterize curcumin-
surviving cell lines. All six curcumin-surviving cell lines
had lower levels of ALDH1A1 when compared with each
corresponding original line, based on ELISA and im-
munocytochemistry. ALDH1A1 is a stem cell marker
that offers cellular protection against cytotoxic drugs
[4,41,64-66]. High ALDH1A1 expression was detected in
a subpopulation of candidate CSCs in all six ESCC cell
lines, and there was considerable variation among the
Figure 6 CD44 immunocytochemistry. Above: two of the six original ESCC lines (YES-1 and YES-2) and their curcumin-surviving lines (YES-1S
and YES-2S) stained with anti-CD44. Below: histograms showing the high-staining subpopulations in the original cell lines (peak marked by
asterisk) which is diminished in the surviving lines. Scale bar =100 μm. There were significant high-staining cell numbers within all original and
surviving lines. The mean intensity of high-staining cells was 446.47 ± 31.21, 438.96 ± 55.38, 463.79 ± 50.66, and 470.20 ± 53.77 for YES-1, YES-2,
YES-1S, and YES-2S, respectively (F=228, p<0.0001).
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lines (Figures 4 & 5). This is also the first report to
analyze ALDH1A1 expression in ESCC lines. Although
in theory CSCs are thought to comprise a small percent-
age of the cancer cell population, the percentage of high
ALDH1A1-staining cells that we found (5.6% to 40.4%.)
is consistent with the high percentage of CSCs identified
in other cancer cell lines [43,67]. Interestingly, the high-
expressing subpopulation was diminished or lost in all of
the surviving lines, indicating that CSC numbers are
altered by curcumin.
Across the six lines, levels of ALDH1A1 and NF-κB
were inversely correlated with sensitivity to curcumin, as
exemplified by KY-5 versus TE-1 (Figure 3). Because one
of the functions of ALDH1A1 and NF-κB is to protect
against cytotoxic agents, the higher levels of both pro-
teins found in cell lines with lower sensitivity to
curcumin suggests that they could be protecting against
curcumin’s effects. Additional studies should examine
whether ALDH1A1 does indeed inhibit curcumin tox-
icity towards cancer cells. Furthermore, the relative
ALDH1A1 expression across the lines as determined by
anti-ALDH1A1 immunocytochemistry agreed with the
ELISA results, as shown in Figures 3–5. Similarly, the
two cell lines with high ALDH1A1 and NF-κB levels,
KY-5 and YES-1, were the least sensitive to curcumin,
whereas the more sensitive lines (KY-10, TE-1, TE-8)
had lower expression of these two markers.
This study examined p65, a subunit of the NF-κB tran-
scription factor, in the ESCC lines. The results support
use of NF-κB as a marker for cancer stem cells because
NF-κB and ALDH1A1 levels were strongly correlated.
NF-κB levels decreased among the three surviving cell
Figure 8 Effects of curcumin on curcumin-surviving cell lines. Overall, the surviving lines showed a small but significant increase in
survivorship to A 40 μM (F=5.132, p=0.031) and B 60 μM (F=8.358, p=0.008) curcumin administered for 30 hrs. Data for the original lines are from
Figure 2. Cell lines are arranged by responses of the original lines to 60 μM curcumin. The mean of three experiments ± SD is shown for 40 and
60 μM curcumin.
Figure 7 Tumorsphere formation. (A) Anchorage-independent spheres formed from YES-2 cell line after 7 days in stem cell medium. (B)
Spheres formed from YES-2S after 2 weeks of cell culture. Scale bar=100 μm.
Almanaa et al. BMC Complementary and Alternative Medicine 2012, 12:195 Page 11 of 15
http://www.biomedcentral.com/1472-6882/12/195
lines that had the highest initial levels of NF-κB (KY-5,
YES-1 and YES-2) according to ELISA. Additionally, the
other three lines showed the same (KY-10) or more NF-
κB expression (TE-1 & TE-8) in the surviving lines, and
this result was confirmed using immunocytochemistry
with the same three lines (TE-1, TE-8, KY-10, data not
shown). The increase in NF-κB but not ALDH1A1 in
two lines could result from the differences between the
functions of these markers. For example, ALDH1A1 is
an enzyme, whereas NF-κB is a cell signaling molecule
and transcription factor that serves in multiple cellular
pathways. This difference suggests that ALDH1A1 may
be a better indicator of stem-like cells.
Whereas most studies measure the activity of the NF-
κB signaling pathway, such as nuclear entry of p65, we
determined the level of p65 in the ESCC lines. Several
studies have shown that the level of NF-κB in cells is
correlated with aggressiveness [68,69], lack of differenti-
ation [70,71], and resistance to chemotherapy [72]. Kang
et al. [68] reported that p65 was expressed more strongly
and regularly in ESCC tissues than in normal esophageal
tissues. Additionally, Tian et al. [69] reported that two
ESCC cell lines (Eca109 and EC9706) showed high p65
expression, and the sensitivity of these cell lines to a
chemotherapeutic agent increased after p65 expression
was inhibited by p65 siRNA transfection. Zhang et al.
[70] reported that the expression level of NF-κB was
higher in poorly or moderately differentiated lung cancer
cells than in well-differentiated cancer cells. Yu et al.
[71] also found that the density of p65-positive cells was
significantly increased in the transition from normal mu-
cosa to adenoma and to adenocarcinoma in colorectal
cells. Hatata et al. [72] reported that a high NF-κB level
in two ESCC cell lines was associated with poor sensitiv-
ity to 5-fluorouracil. The variation in NF-κB level we
found among the six ESCC lines could indicate differ-
ences in the degree of aggressiveness and degree of re-
sistance to chemotherapy.
Interestingly, YES-2 differed from the other lines: Al-
though it had high NF-κB and ALDH1A1 expression, it
showed more sensitivity to curcumin and was the only
line that had no survivors after the 60 μM curcumin
treatment. It is not clear why the YES-2 cell line behaved
differently, and it should be investigated further. Not-
ably, YES-2 is the only one of the six lines derived from
the tumor that was reported to have metastasized in the
patient [73].
Expression of CD44, a stem cell marker, was examined
in two of the lines, YES-1 and YES-2, and in their
curcumin-surviving lines. These original cell lines were
chosen because they had high ALDH1A1 and NF-kB ex-
pression. As observed with ALDH1A1, two subpopula-
tions of cells were recognized in these lines, one with
high and one with low CD44 immunostaining. The
intensity was two times greater in the high-staining cells
than in the low-staining cells. However, the percentage
of highly-stained cells was less then what was observed
in the ALDH1A1 experiment. For YES-1 and YES-2 the
percentage of highly stained cells was 20% and 36.2% for
ALDH1A1, respectively, and 4.82% and 12.11% for
CD44. One way to explain why the high-staining CD44
subpopulation was smaller than the high-staining
ALDH1A1 subpopulation is that the first group may
contain mostly CSCs, whereas the second group may in-
clude progenitor cells derived from CSCs, which are not
fully differentiated but continue to express substantial
amounts of ALDH1A1 [74].
It is generally believed that CSCs are more numerous
in tumors after chemo- and radiation therapy because
they are more resistant than non-stem cells, which along
with their greater aggressiveness makes CSCs a likely
source of tumor recurrence [75-77]. In contrast to
standard therapies, we found that both the high
ALDH1A1 and the CD44 subpopulations were dimin-
ished in the curcumin-surviving lines, suggesting that
the cell populations surviving curcumin contain fewer
stem-like cells. Additional evidence that the surviving
lines have reduced numbers of CSCs was provided by
the ability of YES-2 cells to form tumorspheres, whereas
these were sparse, small, and slow-growing in the YES-
2S cultures. These results are in agreement with a re-
cently published study in which curcumin was found to
inhibit tumorsphere formation in two esophageal adeno-
carcinoma cell lines [59]. The investigators attributed
this effect to inhibition of CSCs by curcumin.
Multiple studies have demonstrated that invasion and
metastasis are mediated by a cellular component that
displays high ALDH1 activity [27,78], suggesting
that ALDH1A1 can be a significant target for cancer
therapy. Therefore, the expression of ALDH1A1 in the
curcumin-surviving cell lines was evaluated to test for
any effect of curcumin on ALDH1A1 expression that is
transmissible through cell division and how this property
may differ among the cell lines. Because it appeared that
we had selected for cells that were intrinsically more re-
sistant to curcumin, we predicted that the surviving lines
would be considerably less sensitive to curcumin
than the original lines. Although one surviving cell line
(YES-1S) showed substantially greater resistance to cur-
cumin, the overall resistance after having been exposed
to curcumin was significant but small when all of the
lines were examined (Figure 8).
If the sensitivity of each line to curcumin depends, at
least in part, on its ratio of CSCs to non-CSCs, then the
loss of CSCs in the surviving cell lines, as shown by the
immunostaining for stem cell markers, suggests that cur-
cumin sensitivity decreases as the proportion of CSCs
declines. However, when comparing across the original
Almanaa et al. BMC Complementary and Alternative Medicine 2012, 12:195 Page 12 of 15
http://www.biomedcentral.com/1472-6882/12/195
six lines, a decrease in sensitivity to curcumin was corre-
lated with increasing stem-like characteristics, as epito-
mized by KY-5. One explanation for this apparent
contradiction is that the range of sensitivity to curcumin
detected across the lines could depend more on genetic
differences among the lines than on sensitivity of CSCs
to curcumin. In support of this explanation, the surviv-
ing lines appear in roughly the same order of sensitivity
to curcumin as the original lines, despite having lost
most or nearly all of their CSCs, as identified by the
number of cells with high ALDH1A1 or CD44 levels.
The specific mechanism causing the reduction in stem
cells by curcumin was not examined in this study, but
we can consider two possibilities. First, the curcumin
may have selectively destroyed the CSCs. Second, curcu-
min may have caused the CSCs to differentiate more fre-
quently into non-CSCs, similar to what has been
described in glioma and PCC4 embryonal carcinoma
cells [79,80]. The surviving population would, in either
case, contain proportionately fewer CSCs. In agreement
with the second scenario, CSCs divide symmetrically,
forming new CSCs, as well asymmetrically, generating
non-CSCs. Curcumin may have altered the balance be-
tween these processes, causing more CSC differentiation.
It has been argued that the cell culture environment
used with cancer cells can determine the percentage of
CSCs present [81]. If the microenvironment of tumors
also plays a major role in determining the CSC versus
non-CSC composition, then curcumin treatments may
improve patient outcome and survivorship by acting on
CSCs. The surviving cell lines may have also changed
while in cell culture during the few passages before they
were tested with the second curcumin treatment. Never-
theless, it is apparent that curcumin reduced the stem
cell properties of the lines by either targeting CSCs or by
inducing a change in CSCs resulting in cells with
reduced stem-like properties. The presence of CSC mar-
kers declined and resistance increased in the surviving
lines, which agrees with our hypothesis that the CSCs in
the surviving lines are reduced in number, because fewer
CSCs would be expected to make the ‘S’ line less sensi-
tive to curcumin.
In agreement with both of these possible mechanisms,
researchers have shown that curcumin can modulate or
eliminate a variety of cellular targets in cancer cells
[82,83]. Although curcumin appears to be effective
against CSCs, its limited bioavailability in the body may
reduce its effectiveness [18,19]. However, Lim et al. [84]
reported that nanoparticle-encapsulated curcumin used
to treat glioblastoma and medulloblastoma cells did re-
duce the number of CD133-positive stem-like cells. Also,
Kanwar et al. [85] reported that difluorinated-curcumin,
a novel curcumin analog, together with other che-
motherapeutic agents reduced the CSC cell markers
CD44 and CD166 in chemo-resistant colon cancer cells.
Our results provide evidence that curcumin alone can
reduce the stem-like cell population in ESCC lines.
Conclusions
The present study demonstrates that curcumin reduces
the number of ESCC cells in a dose-dependent manner.
By comparing the six ESCC lines the results showed that
ESCC cells vary considerably based on CSC properties
and sensitivity to curcumin. This study is the first to es-
tablish and characterize curcumin-surviving subpopula-
tions among cancer cell lines. By comparing the original
ESCC lines and the curcumin–surviving lines we found
that the curcumin-surviving cell lines contain fewer
stem-like cells than the original lines. These data sup-
port clinical applications for curcumin as a chemothera-
peutic agent against cancers, particularly ESCC, rather
than only as a preventative dietary supplement. Contrary
to other chemotherapeutic agents, we predict that the
cells that comprise a recurrent esophageal tumor after
curcumin treatment would contain fewer CSCs than the
original tumor. Because CSCs are considered aggressive
and more metastatic, a tumor developing after curcumin
treatment may be managed more easily than tradition-
ally treated cancers.
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